



US009410206B2

(12) **United States Patent**  
**Hoon et al.**

(10) **Patent No.:** **US 9,410,206 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **LONG NONCODING RNA (LNCRNA) AS A BIOMARKER AND THERAPEUTIC MARKER IN CANCER**

(71) Applicants: **Dave S. B. Hoon**, Santa Monica, CA (US); **Laurent Lessard**, Santa Monica, CA (US)

(72) Inventors: **Dave S. B. Hoon**, Santa Monica, CA (US); **Laurent Lessard**, Santa Monica, CA (US)

(73) Assignee: **JOHN WAYNE CANCER INSTITUTE**, Santa Monica, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 216 days.

(21) Appl. No.: **13/691,716**

(22) Filed: **Nov. 30, 2012**

(65) **Prior Publication Data**

US 2013/0178428 A1 Jul. 11, 2013

**Related U.S. Application Data**

(60) Provisional application No. 61/565,424, filed on Nov. 30, 2011.

(51) **Int. Cl.**  
**C12Q 1/68** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **C12Q 1/6886** (2013.01); **C12Q 2600/112** (2013.01); **C12Q 2600/118** (2013.01); **C12Q 2600/154** (2013.01); **C12Q 2600/156** (2013.01); **C12Q 2600/158** (2013.01)

(58) **Field of Classification Search**  
USPC ..... 435/6.1, 6.12, 6.14, 91.1, 375  
See application file for complete search history.

(56) **References Cited**

**FOREIGN PATENT DOCUMENTS**

WO WO2009046118 A1 4/2009

**OTHER PUBLICATIONS**

ClinicalTrials.gov. ClinicalTrials.gov, Identifier NCT00899574. Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases. Downloaded on Nov. 18, 2015 from <https://clinicaltrials.gov/ct2/show/NCT00899574>.\*

Gibb, et al., "The functional role of non-coding RNA in human carcinomas", *Molecular Cancer* 10, 2011, 38.

Jia, et al., "N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO", *Nature Chem Biol* Oct. 7, 2011, 885-7.

Maris, et al., "Chromosome 6p22 locus associated with clinically aggressive neuroblastoma", *NEJM* 358 Jun. 2008, 2585-93.

Motorin, et al., "5-methylcytosine in RNA: Detection, enzymatic formation and biological functions", *Nucleic Acids Res* 38 2010, 1415-30.

Presner, et al., "The emergence of lncRNAs in cancer biology", *Cancer Discovery* Oct. 1, 2011, 391-407.

Ryan, et al., "Genetic variation in microRNA networks: The implications for cancer research", *Nature Cancer Reviews* Jul. 10, 2010, 389-402.

Verhaegh, et al., "Polymorphisms in the H19 gene and the risk of bladder cancer", *European Urology* 54 Feb. 2008, 1118-26.

Wang, et al., "Molecular mechanisms of long noncoding RNAs", *Molecular Cell* vol. 42 Sep. 2011, 904-14.

\* cited by examiner

*Primary Examiner* — Terra C Gibbs

(74) *Attorney, Agent, or Firm* — Perkins Coie LLP

(57) **ABSTRACT**

Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer.

**13 Claims, 16 Drawing Sheets**

